+

WO2009119992A3 - Percutaneous preparation comprising fentanyl - Google Patents

Percutaneous preparation comprising fentanyl Download PDF

Info

Publication number
WO2009119992A3
WO2009119992A3 PCT/KR2009/001399 KR2009001399W WO2009119992A3 WO 2009119992 A3 WO2009119992 A3 WO 2009119992A3 KR 2009001399 W KR2009001399 W KR 2009001399W WO 2009119992 A3 WO2009119992 A3 WO 2009119992A3
Authority
WO
WIPO (PCT)
Prior art keywords
fentanyl
crovol
polyethyleneglycol
polyethylene glycol
oleyl alcohol
Prior art date
Application number
PCT/KR2009/001399
Other languages
French (fr)
Korean (ko)
Other versions
WO2009119992A2 (en
Inventor
최후균
Original Assignee
조선대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조선대학교산학협력단 filed Critical 조선대학교산학협력단
Publication of WO2009119992A2 publication Critical patent/WO2009119992A2/en
Publication of WO2009119992A3 publication Critical patent/WO2009119992A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a matrix-shaped percutaneous preparation comprising fentanyl, which has at least one kind of penetration enhancer for increasing absorptivity of fentanyl and relieving patient’s pain for a long time. The penetration enhancer is selected from the group consisting of polyglyceryl-3 oleate (Plurol oleique cc497®), polyethyleneglycol-20 almond glyceride (Crovol PK40®), polyethyleneglycol-12 palm kernel glyceride (Crovol A40®), isopropyl myristate (Crodamol IPM®), isopropyl palmitate (Crodamol IPP®), sorbitan monooleate (Span 80®), oleyl alcohol (Oleyl alcohol®), polyethylene glycol 300 (Polyethylene glycol 300®), and polyoxyglyceride (Labrafil 1944®).
PCT/KR2009/001399 2008-03-24 2009-03-19 Percutaneous preparation comprising fentanyl WO2009119992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0026795 2008-03-24
KR1020080026795A KR20090101579A (en) 2008-03-24 2008-03-24 Transdermal drug delivery system containing fentanyl

Publications (2)

Publication Number Publication Date
WO2009119992A2 WO2009119992A2 (en) 2009-10-01
WO2009119992A3 true WO2009119992A3 (en) 2009-12-03

Family

ID=41114441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001399 WO2009119992A2 (en) 2008-03-24 2009-03-19 Percutaneous preparation comprising fentanyl

Country Status (2)

Country Link
KR (1) KR20090101579A (en)
WO (1) WO2009119992A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
KR101353478B1 (en) * 2011-11-04 2014-01-20 주식회사 동일팜텍 Transdermal patch for administering fentanyl

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087276A1 (en) * 2000-05-16 2001-11-22 Samyang Corporation Hydrogel composition for transdermal drug delivery
WO2002026217A2 (en) * 2000-09-29 2002-04-04 3M Innovative Properties Company Composition for the transdermal delivery of fentanyl
US20040234584A1 (en) * 2001-08-24 2004-11-25 Walter Muller Transdermal therapeutic system with fentanyl or related substances
US20060013865A1 (en) * 2002-10-18 2006-01-19 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch for external use comprising fentanyl
US20060039960A1 (en) * 2002-05-28 2006-02-23 Cordes Guenter Plaster containing fentanyl

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087276A1 (en) * 2000-05-16 2001-11-22 Samyang Corporation Hydrogel composition for transdermal drug delivery
WO2002026217A2 (en) * 2000-09-29 2002-04-04 3M Innovative Properties Company Composition for the transdermal delivery of fentanyl
US20040234584A1 (en) * 2001-08-24 2004-11-25 Walter Muller Transdermal therapeutic system with fentanyl or related substances
US20060039960A1 (en) * 2002-05-28 2006-02-23 Cordes Guenter Plaster containing fentanyl
US20060013865A1 (en) * 2002-10-18 2006-01-19 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch for external use comprising fentanyl

Also Published As

Publication number Publication date
WO2009119992A2 (en) 2009-10-01
KR20090101579A (en) 2009-09-29

Similar Documents

Publication Publication Date Title
WO2010016686A3 (en) Nanoemulsion for local administration
EA201170555A1 (en) EMULSIONS WITH A MODIFIED RELEASE FOR APPLICATION TO THE SKIN COVER OR VISUAL SLIM OF
WO2008108286A1 (en) Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
WO2006108405A3 (en) Nanoparticle/active ingredient conjugate
CL2012002126A1 (en) Topical pharmaceutical composition comprising 1` - {[5- (trifluoromethyl) furan-2-yl] methyl} spiro [furo [2,3-f] [1,3] benzodioxol-7,3`-indole] -2` (1`h) -one; and use to treat, a disease or condition such as neuropathic pain, surgical pain, trauma pain, chronic headache, among others.
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2010039654A3 (en) Topical treatment of skin infection
WO2011059324A3 (en) Composition for topical application, uses thereof, applicator device and kit of parts
WO2009119992A3 (en) Percutaneous preparation comprising fentanyl
WO2008025830A3 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
WO2009088673A3 (en) Pharmaceutical composition
WO2009129453A3 (en) Clonidine formulation in a polyorthoester carrier
GB0514344D0 (en) Light protecting-effective cosmetic or dermatological preparations
ATE533509T1 (en) HEART-SLOWING DRUG WITH SHORT-TERM BETA-BLOCKERS AS ACTIVE INGREDIENTS
NZ594486A (en) Narcotic emulsion opioid analgesic formulations for treatment of cancer pain
WO2004071402A3 (en) STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2007071205A3 (en) A taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
WO2008125771A3 (en) Cosmetic use of a debaryomyces hansenii extract
MX2007013449A (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient.
WO2007080117A3 (en) Phyllosilicate formulations for the controlled release of active substances
ZA200609079B (en) Pharmaceutical preparation containing drospirenone for application to the skin
BRPI0518554A2 (en) use of a pde3 inhibitor
GEP20135857B (en) Emollient composition for atopic dermatitis preventive treatment
ATE529127T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ARAZYM FOR THE PREVENTION OF LIVER FUNCTION DISORDER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09724849

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09724849

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载